Lung Cancer News

NEW YORK — Results of the KEYNOTE-189 trial dramatically altered initial treatment for patients with advanced-stage non-small cell lung cancer whose tumors do not harbor targetable alterations, according to a presenter at HemOnc Today New York.

NEW YORK — A combination of immunotherapy and chemotherapy should be used as first line treatment for many patients with non-small cell lung cancer and some patients with small cell lung cancer, according to a presenter at HemOnc Today New York.

NEW YORK — Precision medicine approaches have dramatically altered treatment approaches and improved outcomes for patients with lung cancer, according to a presenter at HemOnc Today New York.

Infertile women appeared more likely to develop certain malignancies than women without fertility problems, according to an analysis of a U.S. insurance claims database.

Pembrolizumab monotherapy continued to show a survival advantage over chemotherapy among certain patients with previously untreated, advanced non-small cell lung cancer, according to an updated analysis of the randomized, phase 3 KEYNOTE-024 trial.

HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment.

Incorporating data from low-dose CT lung cancer screening into a prediction model helped identify patients who would benefit from annual lung cancer screening, according to findings recently published in JAMA Network Open.

Patients who took low-dose aspirin for more than 5 years had a modestly lower risk for lung cancer, according to findings recently published in JAMA Network Open.

Three members of the faculty at City of Hope received awards in recognition of their contributions to the field of oncology.

The FDA granted priority review to three drugs in development for oncology indications.